65 results about "2-Deoxy-D-glucose" patented technology

The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(1,4)-2-amino-2-deoxy-D-glucose, and chondroitin, (C₁₄H₁₉NO₁₄SNa₂)_n; N-acetylchondrosanine (2-acetamide-2-deoxi-D-galactopiranose) and D-gluoronic acid copolymer and/or their dietary and nutraceutically acceptable salts of the same and/or hydrates of the active substance that provide a timed release formulation of the active substance.

Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.

Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and a glycolysis inhibitor, particularly, 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.

Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.

Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies. The systems and methods of the invention may be used to treat drug-resistant or multi-drug resistant cancers.

The present invention relates to compositions and methods for treating cancer, by administering a combination comprising a jasmonate derivative (e.g., methyl jasmonate or a compound of any of formulae I through VII or any of the jasmonate derivatives exemplified by such formulae) and at least one other agent selected from a chemotherapeutic agent (e.g., a nitroso-urea, a platinum compound, a taxane derivative, an antitumor antibiotic) and an inhibitor of glycolysis (e.g., 2-deoxy-D-glucose). The jasmonate derivative and the at least one other agent together provide a therapeutic effect, which is preferably synergistic (cooperative).

The invention discloses a method for preparing nano-silver water solution by modified glucose, which comprises the steps of: mixing 2-(3-carboxy-1-oxopropyl)amino-2-deoxy-D-glucose water solution with the mass percent concentration of 0.01-10% and reducing agent water solution with the mass percent concentration of 0.0001-10% with silver ammonia solution with the mass fraction of 0.01-100g/L according to the volume ratio of 1000: 1: 2-1: 1: 2, and stirring for 5-600min at the temperature of 10-90 DEG C to obtain nano-silver colloidal solution with the average particle size of 1-100nm. The method can be used for preparing the nano-silver colloidal solution by modified glucose 2-(3-carboxyl-1-oxopropyl)amino-2-deoxy-D-glucose, and the obtained nano-silver is even in particle size, good in dispersity, stable in performance and low in irritation to the human body, thus having better medical value.

[PROBLEMS] To find out a specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation and utilize these effects. To provide this rare sugar as a preventive/remedy for diseases with angiogenesis, a cosmetic or a functional food.

[MEANS FOR SOLVING PROBLEMS] A method of controlling the proliferation of vascular endothelial cells characterized by utilizing the vascular endothelial cell proliferation-controlling effect of D-mannose, D-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, L-sorbose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose. A method of inhibiting lumen formation of vascular endothelial cells characterized by utilizing the vascular endothelial cell lumen formation-inhibiting effect of D-allose, D-altrose, D-gulose, D-talose, L-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, D-ribose, L-ribose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose.

The invention relates to a method for improving one or more physical/chemical characteristics, like reduced radiolysis of and the ability to autoclave, a <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution, which method comprises the steps of a) provision of a <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution. The invention also relates to a method for preparing a sterile <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution by autoclaving said <18>F-fluor-deoxy-glucose (FDG)-solution.

The present invention provides a process for the synthesis of 2-deoxy-D-glucose comprising haloalkoxylation of R-D-Glucal wherein R is selected from H and 3, 4, 6-tri-O-benzyl, to obtain alkyl 2-deoxy-2-halo-R-alpha/beta-D-gluco/mannopyranoside, converting alkyl 2-deoxy-2-halo-R-alpha/beta-D-gluco/mannopyranoside by reduction to alkyl 2-deoxy-alpha/beta-D-glucopyranoside, hydrolysing alkyl 2-deoxy-alpha/beta-D-glucopyranoside to 2-deoxy-D-glucose.

Composition methods and kits for diagnosing and treating tumors within a subject. The compositions disclosed comprise: a gold nanoparticle; PEG or derivatives thereof, wherein said PEG or derivatives thereof have a molecular weight of 400 to 1500 Dalton; and a 2-Deoxy-D-glucose, wherein the PEG or derivatives thereof are linked to the gold nanoparticle and to said 2-Deoxy-D-Glucose, and wherein the 2-Deoxy-D-Glucose is linked to the PEG or derivatives thereof at the 2-Carbon position of the 2-Deoxy-D-Glucose.

The invention generally relates to systems and methods for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using a bifunctional compound that inhibits both fatty acid metabolism and glycolysis. Thus, the invention links a fatty acid metabolism inhibitor to a glycolysis inhibitor. More particularly, the invention provides novel bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a glucose derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of 2-deoxy-D-glucose.

The disclosure provides novel topical antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.

The invention discloses a preparation method of 2-deoxy-D-glucose, relating to the field of production of active pharmaceutical ingredients. The preparation method comprises the following steps of: a, taking 3, 4, 6-triacetyl glucose alkenes as raw materials, removing acetyl protection groups in the presence of alkalis and then performing benzyl protection to obtain an intermediate I shown as a formula II; b, acid-hydrolyzing the intermediate I obtained in the step a to obtain an intermediate II shown as a formula III; and c, performing hydrogenolysis on the intermediate II obtained in the step b to de-protect and re-crystallizing to obtain the 2-deoxy-D-glucoses shown as a formula I. Compared with the prior art, the preparation method of the 2-deoxy-D-glucoses has the advantages of simple preparation process, easy purification for products, high yield, low cost and the like, and is more beneficial to achieving large-scale industrial production.

The invention discloses a method of preparing 2-deoxidation-D-glucose. It solves the problems of the complex manufacturing technique and high cost for existing 2-deoxidation-D-glucose. The method includes the following steps: preparing 1.2-deoxidation-2-phenylenemethylamino-D-glucose; preparing 2.2-deoxidation-2- phenylenemethylamino-3,4,5,6-four-O-acetyl-D-glucose; preparing 4.2-deoxidation -2-chorine-3,4,5,6-four-O-acetyl-D-glucose; preparing 5.2-deoxidation-3,4,5,6- four-O-acetyl-D-glucose; preparing 6.2-deoxidation-D-glucose. The raw material of the method is far ranging, and low cost. It has great economic, social, and environment benefit.

The invention relates to a gel material for preventing intestinal adhesion, which is used for preventing peritoneal adhesion after operation. Hyaluronic acid crosslinking preparations for isolating damaged wounds can cause severe adverse reactions during application, such as abdominal pain, abdominal infection, and intestinal adhesion, and even reoperation is performed due to adverse reactions for some patients; the hyaluronic acid crosslinking preparations also have a dissociation phenomenon in the body, and the isolation effect is reduced. The gel material for preventing intestinal adhesion of the invention is a gel system formed by polyacrylamide, a hydrotalcite colloid material, iron ion crosslinked hyaluronic acid gel liquid, 2-deoxy-D-glucose (2-DG) with anti-inflammation and pain-relieving efficacy, tramadol hydrochloride, and acetaminophen. After operation, the gel material is coated directly on a wound; crosslinking effect is generated with fibrin blood clots on the wound; thus the gel material is firmly adhered to the wound; good isolation effect is reached. The medicinal components with anti-inflammation pain-relieving efficacy are directly applied to the wound; and inflammation caused by singly application of hyaluronic acid isolating substances is alleviated.

The invention relates to a Clostridium acetobutylicum strain capable of quickly generating butanol by fermenting xylose and starch, and a screening method and application thereof. The invention discloses Clostridium acetobutylicum, which is classified and named Clostridium acetobutylicumXY16 with the preservation and registration number of CCTCC NO:M2010011. The strain obtained by ion beam mutation and screening of a xylose plate, a 2-deoxy-D-glucose plate, a bromocresol green plate and a resazurin plate can quickly and efficiently generate the butanol by fermenting xylose and starch, has the advantages of high yield of total solvent, high butanol ratio and good repeatability, and is a good strain suitable for industrial production.

The invention discloses a traditional Chinese medicine composition for enhancing the immunity, which is composed of the following components in weight percentage: 5-30% of lentinus edodes extractive, 10-30% of Chinese wolfberry extractive, 10-30% of shikimic acid, 0.5-5% of 2-deoxy-D-glucose and residual amount of anhydrous dextrose. The invention further discloses a preparation method of the traditional Chinese medicine composition and an application of the traditional Chinese medicine composition to enhancing the immunity of livestock. According to the traditional Chinese medicine composition disclosed by the invention, the growth of immune organs of the livestock are obviously accelerated and the organic immunity of the livestock is enhanced; the curative effects on immunosuppression and low functions, which are caused by immunosuppressive diseases, particularly viral diseases, are obvious, and the mortality of the livestock can be obviously reduced; and secondarily, with the adoption of the traditional Chinese medicine composition disclosed by the invention, an antibody titer in the immune livestock can be obviously improved, the in vivo action time of an antibody is prolonged, the humoral immunity is enhanced and the immune effect of vaccines is enhanced; and furthermore, the source of raw materials of the composition is abundant, the production method is simple and the use is convenient.

The invention relates to an improved FDG (2-fluoro-2-deoxy-D-glucose) synthesis method. The method comprises the following steps: 1, leaching: eluting <18>F<-> with a potash/K2.2.2/acetonitrile mixed solution; 2, drying: adding an HPLC acetonitrile solution, uniformly mixing, and drying at 121-123DEG C; 3, a fluorination reaction: adding a mannose triflate/anhydrous acetonitrile solution, and heating under a closed condition to carry out a fluorination reaction; 4, hydrolysis: adding an NaOH solution after the fluorination reaction to carry out hydrolysis; and 5, purifying transfer: adding an HCl solution and disinfected injection water for purifying transfer, wherein a volume ratio of the potash/K2.2.2/acetonitrile mixed solution in step 1 to the HPLC acetonitrile solution in step 2 is 1.5:2, and a volume ratio of the HCl solution in step 5 and the disinfected injection water in the step 5 is 1.5:11. Compared with the prior art, the method provided by the invention has the advantages of simple operation, high synthesis efficiency, high stability and the like.